NSCLC Stage IV Clinical Trial
Official title:
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
This is a multicenter single arm phase II clinical trial. All eligible patients will receive: Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles. Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities.
The hypothesis of this study is that the addition of Atezolizumab (an anti-PD-L1 antibody), to the combination of Carboplatin plus Pemetrexed plus Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for the treatment of patients with stage IV non-squamous, non-small cell lung cancer (NSCLC) will improve progression free survival (PFS) compared with a historical control of carboplatin plus pemetrexed plus bevacizumab. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05543330 -
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04106180 -
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT05215548 -
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
|
Phase 2 | |
| Recruiting |
NCT04042558 -
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
|
Phase 2 | |
| Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
| Recruiting |
NCT04467801 -
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT04027647 -
Phase 2 Study of Dacomitinib in NSCLC
|
Phase 2 | |
| Recruiting |
NCT04768491 -
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
|
||
| Not yet recruiting |
NCT04492969 -
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
|
||
| Recruiting |
NCT04116918 -
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
|
||
| Terminated |
NCT03411473 -
Study of AGEN1884 With Pembrolizumab in 1L NSCLC
|
Phase 2 | |
| Recruiting |
NCT03564197 -
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
|
N/A | |
| Not yet recruiting |
NCT06219317 -
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT04604470 -
Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
|
||
| Recruiting |
NCT05132218 -
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
|
||
| Not yet recruiting |
NCT04136535 -
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
|
Phase 2 | |
| Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT06339554 -
Alectinib-induced Endocrine Toxicity
|
||
| Active, not recruiting |
NCT04549428 -
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
|
Phase 2 | |
| Recruiting |
NCT03647956 -
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
|
Phase 2 |